RxDoctor Payments Data

Vanessa Suggs, APRN

Family · Myrtle Beach, SCNPI 1578269700

Payments from drug & device makers

$3,479in general payments, 2019–2025

Across 139 payments — averaging $25.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$876
  • Phathom Pharmaceuticals, Inc.$589
  • AstraZeneca$459
  • Lilly USA, LLC$271
  • AbbVie$211
  • Corcept Therapeutics$177
  • plus $897 from 17 others

What the payments were for

  • Food & beverage$3,479100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,479 in reported general payments places this provider in the 85th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$114,646
Medicare patients
525
Services billed
3,147

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide26$27,394
EliquisApixaban16$18,717
Albuterol Sulfate HfaAlbuterol Sulfate52$1,133
Doxycycline Hyclate114$940
Levothyroxine Sodium78$841
Atorvastatin Calcium94$792
Ezetimibe35$747
Ondansetron OdtOndansetron53$698
Rosuvastatin Calcium58$578
Losartan Potassium48$555
Prednisone306$497
Lisinopril89$458
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav58$410
Gabapentin28$395
Fluoxetine Hcl15$392

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$876$27,39426 claims
PfizerEliquis$100$18,71716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,248 family providers in South Carolina.

Other family in Myrtle Beach

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →